OTTAWA—Health Canada has approved Pfizer’s antiviral treatment for COVID-19. The authorization posted to the Health Canada website this morning says the treatment is greenlighted for adult patients with mild or moderate COVID-19 who are also at high risk of becoming more seriously ill. Health Canada did not authorize it for use on teenagers. It is also not authorized for use on patients who are already hospitalized because of COVID-19. Paxlovid is a treatment that uses a combination of drugs to prevent the virus that causes COVID-19 from replicating once it has infected a patient. Clinical trials show it was almost 90 percent effective at preventing serious illness in higher-risk patients who received it within the first five days of being infected. More Coming.
-
Recent Posts
-
Archives
- May 2025
- April 2025
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- September 2013
- July 2013
- March 2013
- January 2013
- December 2012
- November 2012
- December 1
-
Meta